At Keros, our mission is to deliver significant clinical benefit to a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. With a focus on developing differentiated product candidates that are designed to alter TGF-β signaling, we aim to target the pathways critical for the growth, repair and maintenance of blood cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. We believe our product candidates have the potential to unlock the full therapeutic benefits of modulating the TGF-β superfamily and provide disease-modifying benefit to patients.

Job Summary

The Director, Program Management, will provide strategic and operational leadership for the rinvatercept (KER-065) development program. This individual will lead cross-functional program planning and execution as rinvatercept advances through clinical development. The ideal candidate will combine strong drug-development program leadership with meaningful experience running clinical trials across Phase 1, Phase 2 and Phase 3.

The successful candidate will move effectively between strategic planning and hands-on execution, anticipate and mitigate risks, drive timely decisions and maintain alignment across Clinical Development, Clinical Operations, Regulatory Affairs, CMC/Technical Operations, Nonclinical, Biometrics and other functions.

Primary Responsibilities

Program Strategy and Leadership

Serve as the program management lead for rinvatercept, partnering with functional leaders to define and execute the optimal global development strategy
Lead the cross-functional program team, including representatives from Clinical Development, Clinical Operations, Regulatory Affairs, CMC/Technical Operations, Nonclinical, Biometrics, Medical Affairs, Commercial and Corporate Strategy
Guide the program through proof of concept, registration-enabling studies, regulatory submissions and potential marketing authorization
Translate development strategy into clear program objectives, operational priorities and measurable deliverables
Mobilize and align the organization around the program strategy and drive timely decision-making through appropriate governance forums
Balance day-to-day program execution with long-range strategic planning

Integrated Development Planning

Create and maintain an integrated strategic development plan covering program goals, value-creation milestones, critical-path activities, cross-functional dependencies, timelines, decision points, assumptions, risks, alternative scenarios, budget and resource requirements
Ensure functional plans are aligned with the overall development strategy and that interdependencies are clearly understood and actively managed
Identify potential gaps, conflicts and constraints before they affect clinical, regulatory or operational milestones
Lead scenario planning to evaluate alternative development approaches and their implications for timeline, resources, risk and program value

Clinical Development and Trial Execution

Partner with Clinical Development and Clinical Operations to plan and execute rinvatercept clinical trials across Phase 1, Phase 2 and Phase 3
Integrate clinical activities with regulatory, CMC, nonclinical, biometrics and other program workstreams
Identify and manage dependencies affecting protocol development, regulatory submissions, site activation, patient enrollment, study conduct, data delivery and clinical readouts
Support transitions between stages of development, including progression from early clinical studies into proof-of-concept and registration-enabling trials
Apply an understanding of neuromuscular and rare-disease trial challenges, including specialized investigator sites, patient recruitment, natural-history considerations, endpoints and global execution
Ensure clinical-trial plans are supported by realistic timelines, budgets, resources and risk-mitigation plans

Cross-Functional Team Effectiveness

Establish and lead an effective operating cadence for program team meetings, working sessions and governance reviews